Jordyn Sava

New Jersey, United States

Assistant Editor at Targeted Oncology

Featured in: Favicon

targetedonc.com Favicon

newsbreak.com Favicon

ajmc.com

cancernetwork.com Favicon

onclive.com Favicon

urologytimes.com Favicon

oncnursingnews.com Favicon

tcnjsignal.net Favicon

cgtlive.com Favicon

curetoday.com + 1 more

Articles

FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML

1 week ago | targetedonc.com | Jordyn Sava

The FDA has granted orphan drug designation (ODD) to SENTI-202 for relapsed/refractory (R/R) hematologic malignancies, including acute myeloid leukemia (AML). SENTI-202 is a first-in-class, off-the-shelf, logic-gated CAR NK-cell therapy engineered to selectively target CD33/FLT3+ malignant cells while sparing healthy bone marrow.
Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights

1 week ago | targetedonc.com | Jordyn Sava

HER2-mutant non–small cell lung cancer (NSCLC) presents a significant unmet need in oncology, particularly concerning targeted therapeutic options. While advancements have been made in other oncogenic drivers like EGFR, ALK, and ROS1, the landscape for HER2 mutations has remained comparatively limited. Current treatment paradigms often rely on cytotoxic chemotherapy, with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) being the only approved agent in the second-line setting.
FDA Approves Tafasitamab in R/R Follicular Lymphoma

1 week ago | targetedonc.com | Jordyn Sava

Tafasitamab-cxix (Monjuvi) is now FDA-approved with lenalidomide (Revlimid) and rituximab (Rituxan) for adults with relapsed/refractory follicular lymphoma (R/R FL). The inMIND trial (NCT04680052) showed a 57% reduction in risk of progression or death, with median progression-free survival (PFS) of 22.4 months vs. 13.9 months in control. Serious infections occurred in 24% of patients; label includes warnings for infusion reactions, myelosuppression, and infection risk.
Atebimetinib Combination Shows Promising Survival Data in Pancreatic Cancer

1 week ago | targetedonc.com | Jordyn Sava

New data from an ongoing phase 2a trial (NCT05585320) suggest that atebimetinib (IMM-1-104), an oral, once-daily novel MEK inhibitor, in combination with modified gemcitabine/nab-paclitaxel (mGnP), may offer significant survival benefits in the first line for patients with pancreatic cancer.
FDA Approves Label Update But Not Expansion for Talazoparib/Enzalutamide in mCRPC

1 week ago | targetedonc.com | Jordyn Sava

The FDA has approved an update to the labeling for talazoparib (Talzenna) in combination with enzalutamide (Xtandi) for men with metastatic castration-resistant prostate cancer (mCRPC).1 This regulatory action incorporates the final overall survival (OS) data for the combination within its existing indication for the treatment of adults with homologous recombination repair (HRR) gene-mutated mCRPC.
PHOX2B PC-CAR T Enters Human Trials Following FDA IND Approval

1 week ago | targetedonc.com | Jordyn Sava

Myrio's PHOX2B peptide-centric (PC)-CAR T therapy has received investigational new drug (IND) application approval from the FDA. A first-in-human trial for Myrio's "breaking HLA restriction" technology is planned to begin. Anticipated enrollment of the first patient is planned for mid-2025. PHOX2B PC-CAR T has received IND application approval from the FDA, enabling its progression to human trials.
FDA Greenlights Perioperative Pembrolizumab in Resectable HNSCC

2 weeks ago | targetedonc.com | Jordyn Sava

Pembrolizumab (Keytruda) is now FDA-approved perioperatively for patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) with a PD-L1 combined positive score (CPS) of ≥1. The KEYNOTE-689 trial (NCT03765918) showed a significant improvement in event-free survival and major pathological response with perioperative pembrolizumab compared with adjuvant radiotherapy with/without cisplatin alone.
Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

2 weeks ago | targetedonc.com | Jordyn Sava

The PROBE trial (NCT04510597) is evaluating the addition of surgery to a standard of care (SOC) immunotherapy-based drug combination vs a SOC immunotherapy-based drug combination alone in patients with metastatic kidney cancer.
Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

2 weeks ago | oncnursingnews.com | Jordyn Sava

Combining nivolumab (Opdivo) with ipilimumab (Yervoy) resulted in lasting clinical benefit vs single-agent nivolumab or standard chemotherapy for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer, per updated results from the phase 3 CheckMate-8HW global trial (NCT04008030) shared at the 2025 American Society of Clinical Oncology Annual Meeting.1 With a median follow-up of 47 (range, 16.7-60.5) months at a data cutoff of...
FDA Grants Fast Track Designation to RAD101 for Imaging of Recurrent Brain Metastases

2 weeks ago | targetedonc.com | Jordyn Sava

The FDA has granted fast track designation to Radiopharm Theranostics’ novel imaging agent, RAD101. This indication is for distinguishing between recurrent disease and treatment effects in brain metastases, including cases involving leptomeningeal disease. RAD101’s clinical utility is currently undergoing investigation in an open-label, multicenter, phase 2b trial (NCT06777433).